MISUSE OF DRUGS ADVISORY COUNCIL

(82nd Meeting)


Monday 10th September 2018


PART A

In attendance -



Note: The minutes of this meeting comprise of Part A and Part B





A5. Any other business.



Date of next meeting A6. The next meeting is on 20th November 2018,

B1. Cannabis.

a. CBD products

provide a paper highlighting the need for a de minimus rule regarding THC content in cannabidiol products. The Council agreed that there was no evidence that small amounts of THC were harmful, and that by not having a de minimus rule it might stifle the beneficial use of cannabidiol. Stated that Guernsey have a de minimus rule which states that the THC content can be allowed up to a 3% of the cannabidiol amount. agreed to check with Guernsey and other jurisdictions as to whether this was the best approach.

b. Licences to cultivate high THC cannabis for research purpose

informed the Council of two companies which had requested licences to grow cannabis with a high THC content for research purposes. The Council noted that, while it did not want to stifle scientific research, under the UN Single Convention on Narcotic Drugs 1961, there was a requirement for a Cannabis Agency. As Jersey did not have one and were subject to the Convention through the UK, the Council would need to seek Home Office advice on the issue.

c. Update on Medicinal Cannabis

stated that legislation was getting nearer, and Jersey would adopt the generic definitions of cannabis derived products as the UK. stated the importance of having uniformity of legislation on this issue. There are two main issues regarding a schedule 2 placing: Firstly, establishing the quality of the medicine. Secondly, establishing who will be the prescribers.

The legislation will include provisions that any product must be manufactured to Good Manufacturing Practice (GMP) standards and that prescribers will need to be specially licensed in order to prescribe any unlicensed cannabis derived medicinal products